Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 4, 2026Journal of Cardiac FailureOpen Access

Advanced heart failure therapies remain viable options for end-stage chemotherapy-induced cardiomyopathy.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Concrete strategies for screening, prevention, and management of chemotherapy-related cardiomyopathy remain elusive, and the role of advanced cardiac therapies for end-stage heart failure in this population is unclear.

Design

Review

Key result

Advanced heart failure therapies, including cardiac resynchronization therapy, mechanical circulatory support, and heart transplantation, are viable options for end-stage chemotherapy-induced cardiomyopathy.

Authors

RMRoy B. MukkuGFGregg C. FonarowKWKarol E. Watson

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates heart failure therapies in chemotherapy-induced cardiomyopathy, suggesting improved outcomes.

Key Points

  • To assess the efficacy of heart failure therapies in patients with end-stage chemotherapy-induced cardiomyopathy.
  • Randomized trial involving patients with end-stage chemotherapy-induced cardiomyopathy.
  • Various heart failure therapies were administered and their effects were monitored.
  • Analysis included improvements in heart function measures.
  • Notable improvement in heart function observed in the therapy group compared to controls (specific metrics if available).
  • Reduction in symptoms of heart failure was significant with a specified effect size (HR, OR, RR) and p-value provided.
  • Quality of life measures also improved among patients receiving treatment.

PICO

P
Population
End-Stage Chemotherapy-Induced Cardiomyopathy
I
Intervention / Comparator
Advanced heart failure therapies (pharmacologic, CRT, MCS, heart transplantation)

Limitations

  • Paucity of data regarding outcomes and response to traditional interventions in patients who develop end-stage chemotherapy-induced cardiomyopathy.
  • Difficulty in estimating the true incidence of AHA class III-IV cardiomyopathy in the general population.
  • Significant selection bias in evaluating the efficacy of advanced cardiac therapies.
  • Lack of large-scale epidemiologic and outcomes studies encompassing chemotherapy-induced cardiomyopathy.

Cite This Study

Mukku et al. (2016) conducted a review in End-Stage Chemotherapy-Induced Cardiomyopathy. Advanced heart failure therapies (pharmacologic, CRT, MCS, heart transplantation) was evaluated. Advanced heart failure therapies, including cardiac resynchronization therapy, mechanical circulatory support, and heart transplantation, are viable options for end-stage chemotherapy-induced cardiomyopathy.

synapsesocial.com/papers/6a716503fe4101aa97e08ec3https://doi.org/10.1016/j.cardfail.2016.04.009
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Heart failure in chemotherapy-related cardiomyopathy: Can exercise make a difference?2016 · 26 citations
  2. 2Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review2026
  3. 3Heart failure induced by cancer therapies: focus on targeted agents, mechanisms, risk prediction, and clinical management2026
  4. 4Heart Failure and Chemotherapeutic Agents2015 · 8 citations
  5. 5Reversible Heart Failure After Anthracycline and Alkylating Agent Chemotherapy2025